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Abstract 
 
 
Paramyxoviruses include a number of important human pathogens, including measles 
virus, mumps virus, and the human parainfluenza viruses (hPIV) 1-4, as well as several 
animal pathogens, such as Sendai virus, Nipah virus and Hendra virus.  The creation of 
effective drugs and vaccines against this family of viruses would play an important role 
in decreasing the prevalence of these viruses and contributing to the health of both 
humans and animals worldwide.  The purpose of this work was to determine how the 
fusion (F) protein is regulated with a focus on the heptad repeat B (HRB) region of the F 
protein located in the ectodomain, directly adjacent to the transmembrane domain.  This 
region has been suggested to play important roles in the initiation of fusion  
(Gravel 2003) as well as in the formation of the final hairpin structure that drives fusion 
(Russell 2001).  My investigation of the HRB region of the parainfluenza fusion (F) 
protein has been to characterize the structure of this domain in the pre-fusion form of the 
F protein in order to better understand the role it plays in fusion.  An understanding of 
how F protein conformational changes are regulated may lead to the creation of more 
effective therapies against paramyxoviruses in general.  A crystal structure obtained from 
the pre-fusion PIV5 F protein (Yin 2006) reveals that the HRB domain is in a triple 
stranded coiled coil conformation.  However, in order to obtain the structure, a 
trimerization domain was used for structure stabilization.  It is not known if the 
trimerization domain influenced the resulting crystal structure.  My research has 
investigated the structure of the HRB region by creating mutations in both the pre-fusion 
hPIV3 F protein and peptides derived from the HRB region.  Although much work still 
remains, preliminary results are consistent with the HRB region of the hPIV3 F protein 
forming a triple stranded coiled coil in the pre-fusion conformation. 
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Chapter 1.  Introduction 
 
 
Brief Overview of Paramyxoviruses 
 
 Paramyxoviruses include a number of important human pathogens, including measles 
virus, mumps virus, respiratory syncytial virus, and human parainfluenza viruses (hPIV) 
1-4, as well as several animal pathogens, such as Sendai virus, and newly emerging, 
highly pathogenic Nipah virus and Hendra virus.  The interest in viruses composing this 
family has been due to their high infectivity (measles virus), high prevalence worldwide 
(the hPIVs), and their economic impacts on animal and poultry rearing (rinderpest virus 
and Newcastle disease virus).  The impact of this family of viruses can be seen in the 
World Health Organization’s attempt to eradicate measles as well as the push for 
vaccines protecting children against hPIV3, a pathogen that hospitalizes 30,000 children 
in the United States alone and is almost always fatal in those with immunodeficiencies 
[1].   
 
Pathogens belonging to the family Paramyxoviridae are divided into subfamilies 
Paramyxovirinae and Pneumovirinae which are differentiated based on nucleocapsid 
structure, number of encoded proteins, and differences in attachment proteins.  The 
subfamily Paramyxovirinae is further divided into five genera: Rubulavirus (Mumps), 
Avulavirus (Newcastle disease), Respirovirus (hPIV3, Sendai virus), Henipaviruses 
(Nipah virus, Hendra virus), and Morbillivirus (measles virus).  The division of 
Paramyxovirinae genera is based on the presence or absence of neuraminidase activity 
and antigenic cross-reactivity [2].   
 
All paramyxoviruses are enveloped, single-stranded, negative-stranded RNA viruses.  
The negative-stranded RNA genome serves two main functions including being a 
template for mRNA synthesis as well as being a template for synthesis of the positive 
antigenome strand.  The antigenome strand is created only after mRNA synthesis and is 
essential in creating more negative stranded RNA for packaging into virions.  Also 
included in the paramyxovirus structure are the nucleocapsid protein (N), the 
phosphoprotein (P), and the large protein (L).  The nucleocapsid protein is responsible for 
a variety of functions including interaction sites for assembly of the virion, and protection 
of the RNA genome from protease digestion [2].  The L protein functions as an RNA 
dependant RNA polymerase and interacts with the P protein which is important for 
activation of the enzyme complex and enhanced stability of the L protein [3].   
 
The lipid envelope surrounding the virus is derived from the plasma membrane of the 
host cell and contains two surface glycoproteins, an attachment protein (HN, H, or G) and 
a fusion (F) protein which mediates pH independent fusion of the viral and host cell 
membranes.  For Rubulaviruses and Respiroviruses, the attachment glycoprotein is the 
hemagglutinin neuraminidase (HN) protein which binds sialic acid receptors on host cell 
membranes and is necessary for the release of viral particles from infected cells.  The 
binding of the HN protein to sialic acid is necessary for the activation of the F protein to 
cause fusion of the viral and cell membranes.  To prevent cell agglutination, the HN also 
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contains neuraminidase activity which cleaves sialic acid and allows the escape of 
budding viruses from the host cell membrane.     
 
 
Changes in F Protein Conformation 
 
 The F protein of paramyxoviruses is a class I fusion protein.  Class I proteins are 
defined by an α-helical coiled coil structure and include proteins such as the influenza 
HA protein and HIV gp-41 protein.  The F protein is initially expressed as an inactive F0 
precursor which is subsequently cleaved intracellularly by the protease furin.  The 
resulting metastable fusion-capable complex is composed of two disulfide linked 
subunits, a membrane distal F1 subunit and a membrane proximal F2 subunit.  The F 
protein also contains a hydrophobic fusion peptide, two 4-3 heptad repeat regions, and a 
transmembrane domain.  Upon triggering by the HN protein, the F protein undergoes a 
series of conformational changes thought to include several distinct intermediates  
(Fig. 1-1).  The molecular mechanism of triggering by HN remains unknown although 
there is evidence that the stalk of the HN protein directly interacts with the head of the F 
protein [4].  The first conformational change in the F protein occurs in HRB as an early 
fusion intermediate defined by the opening up of the triple stranded coiled coil 
conformation of HRB [5].  Based on the prefusion structure of PIV5 solved by Yin, et al. 
in 2006 [6] residues 443, 447, and 449 at the n-terminal end of the HRB region are 
important in altering the triggering capabilities of the F protein [7, 8].  Next, the HRA 
region refolds into a triple stranded coiled coil which propels the fusion peptide into the 
host cell membrane [5].  Previous studies in the HRA region show that residues in this 
area also affect the fusion capabilities of the F protein [9].  Finally the HRB region of the 
F protein swings up and binds in an antiparallel manner to HRA forming a six helix 
bundle bringing the viral and cell membranes to cause fusion [5]. 
 
 
The Heptad Repeat B (HRB) Region 
 
 Based on previous studies implicating the HRB region in the initiation of fusion [10] 
as well the role of HRB in the formation of the final fusogenic hairpin structure that 
drives fusion [5] the study of the HRB can be beneficial to the further understanding of 
paramyxovirus fusion.  The uncleaved prefusion structure of PIV5 [6] and the post fusion 
structures of hPIV3 and NDV [11] provide a visual representation of HRB 
conformational changes and are important tools in furthering our knowledge.  However, 
despite the importance of residues at the N-terminal region of HRB, very few 
experiments have explored the residues closest the transmembrane domain.  In order to 
obtain a more accurate understanding of this area we chose hPIV3 for which the final 
fusogenic structure has been already solved.  Questions about the HRB region arise from 
the methods used to obtain the prefusion structure of closely related PIV5.  When Yin, et 
al. set out to determine the crystal structure for the prefusion structure of PIV5, they 
found that when the transmembrane domain was deleted they only obtained structures of 
the final fusogenic hairpin structure implicating the transmembrane  
A. 
X Fusion Peptide   HRA   HRB   
TM 
Domain   CT   
Cleavage Site 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. 
Viral Membrane 
Host Cell Membrane 
 
Figure 1-1.  Schematic of the Paramyxovirus F Protein.  (A)  Structure of the F protein.  The intracellular site of cleavage of F0 into 
F1 and F2 subunits is represented by the X.  The fusion peptide (green), heptad repeat A (red), and heptad repeat B (blue) are also 
represented along with the transmembrane domain and cytoplasmic tail (gray, dotted line).  (B)  The series of conformational changes 
believed to lead to viral and host cell membrane fusion.  Ribbon diagrams represent the pre-fusion PIV5 F0 [6] and the post-fusion 
hPIV3 F structure [11].  Conformational changes are based on biochemical studies [5, 7, 8] and are represented here schematically. 
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domain as important in the stabilization of the metastable prefusion form of the F protein.  
In order to stabilize the prefusion structure without hindering the crystallization process, 
a trimerization domain (GCN4) was attached to the c-terminus of the HRB region in 
place of the transmembrane domain and cytoplasmic tail [6].  The results based on the 
crystal structure obtained by Yin has been the basis for our views on how the F protein 
functions and how it promotes viral and cell membrane fusion.  Despite suggestions that 
a trimerization domain does not affect the HRB structure [6] many fundamental questions 
arise.  Does the addition of a trimerization domain influence the secondary structure of 
the HRB region?  Through studies based in HRB directly adjacent to the transmembrane 
domain we hope to study the previous model of the prefusion structure of the 
paramyxovirus F protein to determine role of the trimerization domain.  Not only will 
these studies shed light on the true secondary structure of the HRB region, they will help 
us to answer questions about the initiation of fusion and increase our understanding on 
how to create effective treatments and vaccines against some of the world’s most 
prominent viral pathogens. 
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Chapter 2.  Materials and Methods 
 
  
Cell Culture 
 
 Monolayer cultures of Vero (ATCC CCl-81) cells, BHK-21 cells (ATCC CCL-10), 
and BSR-T7/5 cells [12] were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) 
containing 10% fetal calf serum (FCS), 1% glutamine, 1% penicillin, and 1% 
streptomycin.  To preserve the plasmid containing the T7 promoter, geneticin in a final 
concentration of 1 mg/ml was used to supplement BSR T7/5 cell media every other 
passage.  BHK-21 cells were supplemented with 10% tryptose phosphate broth.  All cell 
lines were maintained at 37°C and 5% CO2. 
 
 
Plasmids  
  
 Primers were designed according to the recommendations of the QuickChange site-
directed mutagenesis kit (Stratagene) for creating point mutations in pGEM3X hPIV3 F 
plasmids [13] which have been described previously.  Mutations of interest were chosen 
based on computer modeling completed by Helori Gaude and include S477A, S477K, 
N478D, N478K, and G485K.  Mutants I484D, I484G, and G485A had been previously 
created in the pGEM3X background by Charles J. Russell.  Primers for the introduction 
of single mutations extended at 10 - 22 nucleotides on each side of the mutation of 
interest (Fig. 2-1).  A list of primers used for mutagenesis can be found in Table 2-1. 
  
Mutations in pGEM3X hPIV3 F plasmids were subcloned into the pCAGGs hPIV3 F 
plasmid previously described [14] or into the MBP plasmid pMAL – c2E (New England 
Biolabs, N8066S).  All pGEM3X hPIV3 F plasmids inserts containing the mutation of 
interest were subcloned into pCAGGs hPIV3 F or pMAL-c2E plasmid vectors by 
digestion with ClaI and XhoI or BamHI and SalI respectively.  The nucleotide sequences 
of all constructed plasmids was confirmed by the Hartwell Center of St. Jude Children’s 
Research Hospital. 
 
 
Transient Expression of Viral Envelope Glycoproteins 
 
 Monolayers of Vero cells (ATCC CCl-81) in six-well dishes (at 85%-95% confluence) 
were transiently transfected by using the Lipofectamine Plus Expression System 
(Invitrogen) with 1 - 2 μg pCAGGs C243 F protein DNA, 1 μg pCAGGs C243 HN 
protein DNA, or both.  Transfected cells were incubated at 37°C for 2 hr.  Transfection 
media was removed from the cells and DMEM containing 10% fetal calf serum and 1% 
glutamine was added.  Cells were incubated for 16-18 hr at 37°C and then treated as 
described in subsequent experiments. 
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 Forward Primer 
nnn  
Site of 
Mutagenesis 
Plasmid DNA Template 
5’ 
5’ 
3’ 
3’ 
Reverse Primer 
6-10 bases 
6-10 bases 8-12 bases 
8-12 bases 
 
 
Figure 2-1.  Primer Design.  Primers for mutagenesis were designed using the template 
represented here.  Forward and reverse primers were homologous to double stranded 
plasmid template DNA with the exception of the site of mutagenesis.  
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Table 2-1.  Primers Used in pGEM3X hPIV3 C243 F Mutagenesis. 
 
Mutation     Primer Name                 Sequence (5’ – 3’) 
  S477A      ARC1006 (Fwd)  ggataagaagggcaaatcaaaaactagattccattg 
         ARC1007 (Rev)  gtttttgatttgcccttcttatccattcttttgac 
 
  S477K      ARC1008 (Fwd)  ggataagaaggaaaaatcaaaaactagattccattg 
        ARC1009 (Rev)  gtttttgatttttccttcttatccattcttttgactc 
 
  N478D      ARC1000 (Fwd)  gataagaaggtcagaccaaaaactagattccattggaaattg 
         ARC1001 (Rev)  gaatctagtttttggtctgaccttcttatccattcttttgac 
 
  N478K      ARC1014 (Fwd)  gataagaaggtcaaaacaaaaactagattccattggaaattg 
        ARC1015 (Rev)  gaatctagtttttgttttgaccttcttatccattcttttgac 
 
  G485K      ARC1004 (Fwd)  gattccattaaaaattggcatcaatctagcaccac 
        ARC1005 (Rev)  gatgccaatttttaatggaatctagtttttgatttg 
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Radioimmunoprecipitation 
 
Vero cells expressing either wild type (wt) or mutant F proteins were maintained in 
methionine- and cysteine- free DMEM for 30 min.  Cells were then labeled for 15 min in 
0.5 ml methionine- and  cysteine- free DMEM containing 20 mM HEPES buffer (pH 7.3) 
and 50 μCi [35S] (Perkin Elmer).  In order to allow the protein to reach the cell surface, 
the cells were then washed once with phosphate buffered saline (PBS) containing 0.1 g/L 
magnesium chloride and 0.1 g/L calcium chloride (PBS +) and chased with 3 ml of 
DMEM containing 2 mM Methionine, 2 mM cysteine, and 20 mM HEPES buffer (pH 
7.3) for 120 min.  Samples were lysed with ice-cold radioimmunoprecipitation assay 
buffer (RIPA) containing 0.2 µg/ml aprotinin, 10 mM iodoacetamide, and 1 mM 
phenylmethylsulphonyl fluoride (PMSF).  The lysate was spun at 67,000 x g for 15 
minutes in an Optima TLX ultracentrifuge (Beckman Coulter) as described previously 
[15].  
  
The supernatant was incubated on a nutator overnight (18 to 22 hours) at 4°C with 7 μl 
of A0028 rabbit anti-tail peptide polyclonal antibody.  60 μl of Protein A Sepharose CL-
4B (GE Healthcare) suspended in a 50-50 slurry in 50 mM Tris (pH 7.0) was added to 
immune complexes for 1 hr at 4°C.  Samples were washed three times with RIPA buffer 
containing 0.3 M NaCl, three times with RIPA buffer containing 0.15 M NaCl, and once 
with SDS wash II (5 mM NaCl, 1 M Tris, 0.25 M EDTA, pH 7.4).  Samples were 
resuspended in 50 μl of 4x NuPAGE® SDS Sample Buffer (Invitrogen).  The samples 
were then boiled for 5 min, centrifuged in an Eppendorf microcentrifuge, and fractionated 
on a 12% NuPAGE  Bis- Mini gel (Invitrogen).  
 
Gels were stained for 1 hr in SimplyBlue SafeStain (Invitrogen).  Gels were then 
changed over into 1x Gel Drying Solution (BioRad) for 30 min and dried at 70°C for 1 hr 
on a BioRad Gel Dryer.  Visualization of protein bands were obtained using a Typhoon 
9200 phosophoimager (GE Healthcare) and quantified using ImageQuant 5.2 software 
(Molecular Dynamics). 
 
 
Transformation  
 
To prevent codon bias leading to possible delayed translation or RNA degradation of 
hPIV3 F protein BL-21 CodonPlus(DE3)-RIPL cells (Stratagene) were used for 
transformation.  The bacteria were thawed on ice and 100 µl were aliquoted into pre-
chilled 14 ml polypropylene round-bottom tubes (Falcon).  XL 10-Gold β-
mercaptoethanol (Stratagene) was diluted 1:10 and 2 µl was added to each 100 µl aliquot 
of bacteria.  The bacteria mix was incubated on ice for 10 min with gentle swirling in 2 
min increments.  Plasmid DNA (1–50 ng) was added to each tube containing BL-21 
bacteria and the reaction was incubated for 30 min on ice.  The reactions were then heat-
pulsed for 20 sec in a 42ºC water bath and immediately incubated on ice for 2 min.  900 
µl of S.O.C. medium (Invitrogen) was added to each reaction followed by a 1 hr 
incubation at 37ºC with shaking.  After incubation, 200 µl of transformed bacteria were 
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spread onto plates containing LB agar and ampicillin.  Plates were incubated overnight at 
37ºC. 
 
 
Peptide Induction 
 
A single bacterial colony was used to inoculate 10 ml of LB broth containing 50 µg/ml 
of chloramphenicol and was incubated at 37°C with shaking overnight.  After incubation 
the 10 ml culture was pipetted into 500 ml of LB broth without any selection antibiotics.  
The culture was incubated at 37ºC with shaking and monitored for an O.D600 of 0.5.  To 
induce peptide production 100 µM isopropyl β-D-1-thiogalactopyranoside (IPTG) was 
added to the culture at 37°C with shaking.  Two hr post-induction the culture was spun 
down at 4°C for 15 minutes at 2,900 x g on a Beckman Avanti J-251 refrigerated 
centrifuge.  The pellet was weighed and kept at -20ºC.  The HRA peptide was induced 
separately by the Protein Production Facility at St. Jude Children’s Hospital. 
 
 
Lysis of BL-21 CodonPlus(DE3)-RIPL Cells  
 
To extract peptides lysis buffer containing 20 mM Tris and 200 mM KCl was added to 
pelleted BL-21 cells.  Lysis buffer was added in volume twice the weight of the pellet.  5 
mM β-mercaptoethanol and 1 mM PMSF were then added and the pellet was vortexed 
until completely resuspended.  Cells were then sonicated with a VirSonic 60 (VirTis) for 
2 min in 30 sec intervals.  Samples were spun down in an Eppendorf microcentrifuge for 
30 min at 4°C.  The supernatant was collected and further centrifuged for 30 min at 
27,000 x g at 4°C on an Avanti J-251 centrifuge (Beckman).     
 
 
Column Purification   
 
Supernatant containing the peptide of interest was loaded into a Nickel (Ni) column 
washed once with 3 bed volumes of equilibration buffer containing 20 mM Tris and 300 
mM NaCl and the flow through collected.  To reduce non-specific binding the column 
was then washed once with a low imidazole buffer containing 20 mM Tris, 300 mM 
NaCl, and 20 mM imidazole.  Each wash was 3 bed volumes and the flow through 
collected in 1 ml fractions.  To elute peptides from the column a high imidazole buffer 
containing 20 mM Tris, 300 mM NaCl, and 250 mM imidazole was used and 1 ml 
fractions collected.  Peptides were visualized in a 16% Tricine gel (Invitrogen) under 
reducing conditions and stained with Coomassie stain. 
 
 Peptide samples obtained from the Protein Production Facility of St. Jude Children’s 
Research Hospital had been previously purified by affinity chromatography on a Ni 
column and cleaved with thrombin.  To remove thrombin from the peptide solution to 
prevent sample degradation, peptides were loaded into Benzamidine Sepharose 6B (GE 
Healthcare) column and the flow through collected in 1 ml fractions.  The column was 
washed with 3 bed volumes of binding buffer containing 20 mM Tris and 200 mM NaCl 
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and collected in 1 ml fractions.  Fractions containing peptides were identified by 
visualization on a 16% Tricine gel (Invitrogen) and stained with Coomassie stain. 
 
 
Cleavage of Peptide Constructs with Factor Xa 
 
Peptide samples were cleaved with Factor Xa protease (FXa) (New England Biolabs) 
to remove the His tag and thrombincleavge site from the N terminus of the peptide.  FXa 
was added to samples in a 1 to1 ratio of sample to FXa and incubated 16 – 18 hr at 37°C.  
An additional 250 µl of FXa was added to samples in low pH solutions and the sample 
incubated at 37°C for another 16 – 18 hr.  Cleaved samples were kept at 4°C. 
 
 
Concentration of Peptides 
 
Due to the low concentration of peptide found in each fraction after column 
purification samples were concentrated in order to increase visualization and 
effectiveness of subsequent assays.  Samples were loaded into 0.5 ml 3,000 MWCO 
Centrifugal Filter Devices (Millipore) and centrifuged for 1 hr at 4°C on an Eppendorf 
microcentrifuge. 
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Chapter 3.  Regulation of Full-Length hPIV3 F Protein Expression and Fusogenicity 
by Residues in HRB 
 
 
Introduction 
  
 With the recent determination of the hPIV3 and closely related NDV post-fusion 
conformations [11, 16] and the PIV5 pre-fusion conformation [3] of the paramyxovirus F 
protein, there have been valuable insights into how the F protein mediates viral and cell 
membrane fusion.  Biochemical studies have characterized dramatic conformational 
changes occurring in the paramyxovirus F protein [2, 17, 18] and additional studies have 
investigated residues directly adjacent to the HRB region which have been shown to be 
important in the formation of F fusion intermediates in PIV5 [4, 7].  However, HRB 
residues directly adjacent to the transmembrane domain remain largely unexplored but 
are key in determining F protein stability and the initiation of fusion. 
 
 Various studies have determined the interaction of the hemagglutinin neuraminidase 
(HN) protein with the HRB region [9] and have explored the relationship between the 
triggering of the F protein and the conformational changes in HRB [2].  However, 
because the structure of the pre-fusion F protein has never been determined without the 
addition of a trimerization domain, there are only theories surrounding the triple stranded 
coiled coil conformation of the HRB region.  Based on a series of computer generated 
models by Helori Gaude, mutations to destabilize the F protein and therefore initiate the 
conformational changes into the final fusogenic structure can be assessed and can 
therefore determine the structure of the HRB region adjacent to the membrane.  Although 
determining structure is vital to this investigation, biochemical studies on peptides 
derived from this region are still underway while F ectodomain studies are largely 
complete.  It is because of this that we begin our analysis with the hPIV3 F ectodomain 
and conclude with the peptide analysis.  We hypothesize that the HRB region of the F 
protein is found in a triple stranded coiled coil conformation when in the native pre-
fusion state.  
 
 
Materials and Methods 
 
  
 Mutagenesis and Subcloning pGEM3X Mutations into a pCAGGs Background.  To 
create point mutations primers were designed and PCR reactions set up as previously 
described in Chapter 2.  The mutants I484D, I484G, and G485A in pGEM3X were 
created previously by Charles J. Russell, Ph.D.  Full length F protein ectodomain 
sequences containing mutations of interest were subcloned into the pCAGGs hPIV3 F 
background [14] using ClaI and XhoI restriction sites.   
 
   
Total F0 Protein Expression.  16 - 18 hours after transfection, Vero cells were 35S 
labeled for 10 minutes, washed twice using PBS +, and chased for 0 minutes. 
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Radioimmunoprecipitation was carried out as described and protein expression was 
visualized and quantified as stated in Chapter 2. 
 
 
Cleavage Efficiency.  16 – 18 hours after transfection, Vero cells were 35S labeled and 
chased as described in Chapter 2.  12% β-mercaptoethanol was added to each sample 
before gel electrophoresis in order to break disulfide bonds between F1 and F2 and allow 
for better visualization on a 12% Bis-Tris gel (Invitrogen). 
 
 
Biotinylation of Surface F Protein.  For cell surface biotinylation experiments, Vero 
monolayers in 6cm diameter dishes (80-90% confluence) were transfected as previously 
described. 16 - 18 hours post-transfection, Vero cells were washed twice using PBS +, 
radiolabeled, and chased for 120 minutes.  Samples were then biotinylated twice for 15 
minutes with EZ-Link Sulfo-NHS-SS-biotin (Pierce) in a concentration of 2 mg per 1 ml 
of PBS+ (pH 8.0) at 4°C.  The cells were washed once with PBS + and once with PBS + 
(pH 8.0) containing 50 mM glycine to remove excess biotin.  The cells were then 
radioimmunoprecipitated as described in Chapter 2 and incubated with 15 µl antibody 
[15].   
 
After the addition of 120 µl of Protein-A Sepharose and subsequent washes, the 
samples were resuspended in 100μl of 50 mM Tris (pH 7.4) containing 0.5% SDS, 
vortexed, boiled for 5 minutes, and centrifuged for 1 minute at 14K in an Eppendorf 
5417R.  The supernantant was then split into two 50 μl fractions.  One fraction 
represented total radiolabeled F protein and was kept at 4°C for direct loading into a 12% 
NuPAGE  Bis- Mini gel (Invitrogen).  1 ml of Streptavidin Agarose buffer ( 0.15 M 
NaCl, 20 mM Tris [pH 8.0], 5 mM EDTA. 1% Triton X, 0.2% BSA) and 100 µl of 
Streptavidin Agarose Resin in a 50/50 slurry (Thermo Scientific) was added to the second 
fraction which was incubated overnight on a nutator at 4°C.  The samples were then 
washed three times with RIPA buffer containing 0.3 M NaCl, once with RIPA buffer 
containing 0.15 M NaCl, and once with SDS wash II (5 mM NaCl, 1 M Tris, 0.25 M 
EDTA, pH 7.4). 
 
 
Syncytia Assay for Cell-Cell Fusion.  Monolayers of BHK-21 cells grown in 6-well 
plates were transfected with pCAGGs C243 F and pCAGGs C243 HN protein DNA as 
described previously.  At 20 hours post-transfection cells were stained with Hema 3 
solution (Fischer) according to manufacturer instructions.  A Nikon D70 digital camera 
attached to a Nikon Eclipse TS100 inverted microscope was used to capture 
representative fields of each sample.   
 
To quantify differences between mutants, the number of syncytia per field of view and 
the number of nuclei per syncytia formation were counted over 30 fields of view at 20x 
magnification on a Nikon TE300 Eclipse inverted microscope.  Analysis of syncytia 
counts were completed using Microsoft Excel.   
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Luciferase Reporter Gene Assay for Cell-Cell Fusion.  To quantify membrane fusion 
a luciferase reporter gene assay was performed Vero cells were transfected with a T7 
Luciferase Control DNA (Promega), pCAGGs C243 hPIV3 F, and pCAGGs C243 HN 
DNA as described in Chapter 2.  16 – 18 hours post-transfection BSR T7/5 cells were 
washed and spun down for 5 minutes at 1,800 rpm in a Centra CL3 centrifuge (Thermo).  
The supernatant was removed, the BSR T7/5 cells were resuspended in DMEM media 
without antibiotic, and the BSR T7/5 cells were overlaid onto the Vero cells.  Vero and 
BSR T7/5 cells were incubated together for 5 hours at 37ºC in 5% CO2 [4].   
 
After incubation the cells were washed twice with PBS + and 500 µl of Reporter Lysis 
Buffer (Promega) was added to each sample.  Cells were then lysed by placing them at -
20°C overnight and thawing them at room temperature the following day.  The lysates 
were then spun down for 5 minutes at 14,000k in an Eppendorf 5417R at 4ºC and 150 µl 
of each sample was loaded into a 96 well plate.  Luciferase activity was determined using 
Luciferase Assay Substrate (Promega) and a Veritas Microplate Luminometer (Turner 
Biosystems) per manufacturer’s recommendations.  All luciferase reporter gene assays 
were carried out in triplicate.   
 
 
Results 
 
 
 Mutations in the HRB Region of the hPIV3 Ectodomain Do Not Decrease 
Expression of the F Protein.  Computer modeling by Helori Gaude to determine the 
mutants of interest for this project focused only on the effect of the mutations in peptides 
derived from the full-length hPIV3 F protein but were not able to predict the effect these 
mutations would have on the overall expression and processing of the F protein.  
Computer models were created by inserting the amino acid sequence of hPIV3 into a 
structure based on the crystal structure obtained by Yin et al. for the closely related 
paramyxovirus PIV5 [3].  To determine the effects of mutations on total expression of the 
hPIV3 F protein the amount of uncleaved F0 was measured by a 10 minute 
radioimmunoprecipitation [15]   with a rabbit anti-tail polyclonal antibody.  F0 expression 
was analyzed by SDS-PAGE under denaturing conditions but in the absence of reducing 
agents.  Mutations of both “d” residues on the interior of the triple stranded coiled coil 
(S477 and I484) and “e” residues on the exterior of the structure (N478 and G485) in the 
HRB region of the hPIV3 F protein did not decrease expression although there was a 
noticeable increase in expression seen in mutants N478D and I484D (Fig. 3-1).  A slight 
decrease was observed in S477A but expression was still seen at levels 90% of wild-type 
expression (Table 3-1). 
 
 
Surface Expression of Mutant F Proteins Is Comparable to wt F.  To determine if 
mutations would affect the cell surface expression of the F protein, cells were treated 
with the biotinylation reagent EZ-Link Sulfo-SS-biotin (Pierce) [15].  The cells 
underwent radioimmunoprecipitation with a rabbit anti-tail polyclonal antibody and pull-
down with Streptavidin Agarose Resin (Thermo Scientific).  Results indicate that mutant  
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Figure 3-1.  hPIV3 F0 Protein Expression.  (A)  Vero cells expressing hPIV3 wild-type 
(wt) or mutant F proteins were labeled with [35S] methionine for 10 minutes.  Peptides 
were immunoprecipitated with a polyclonal antibody against the cytoplasmic tail of the F 
protein and analyzed on an SDS-PAGE gel under denaturing conditions and in the 
absence of a reducing agent.  (B)  Ratios of hPIV3 mutant F proteins as a percentage of 
wild-type.  Solid line signifies 100% hPIV3 wild-type F expression. 
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Table 3-1. Phenotypes of Wild-type and Mutant hPIV3 F Proteinsa. 
 
 
              Total  Cell Surface    Cleaved                    Syncytiae                         Membrane Fusion      Expected 
hPIV3 F protein        HRB sequence   F0b    Expressionc   F1/(F1+F0)d     Syncytia/Fieldf      Syncytial             (Luciferaseh )          Phenotypei 
                                             Nuclei/Fieldg        
wild-type (wt)    SNQKLDSIGN   100       100        0.40     6.1              63.8             100±11             - 
S477A         A.........      90         96      0.47     8.4                 89.1             127±13        destabilize 
S477K         K.........    115       146      0.55     5.7              40.5               31±7       little / no effect 
N478D         .D........    145       132        0.43               6.8                73.4             126±13     destabilize 
N478K         .K........    110       150      0.53             10.6              107.3             124±1          destabilize 
I484D         .......D..    128       101         0.46     6.8               50.0               67±14     stabilize 
I484G         .......G..    112         92      0.48     5.6              49.0               39±7          little / no effect 
G485A              ........A.    112       172        0.43     8.7              91.8             122±11     destabilize 
G485K         ........K.     101       132        0.50     9.4              88.3               97±21     stabilize 
 
 
a   hPIV3 F proteins expressed from pCAGGS DNA in Vero cells. 
b   Total F0 expressed after 10 min of [35S] methionine labeling.  Data is normalized to wild-type hPIV3 F. 
c   Cell surface expression determined by biotinylation.  Data is normalized to wild-type hPIV3 F. 
d   Cleavage efficiency of hPIV3 F protein after 10 min of [35S] methionine labeling and 2 hour chase. 
e   Cell-cell fusion as determined by syncytia assay.  
f    Average number of syncytia (fusion of 3 or more nuclei) per field of view at 20x magnification. Reported numbers represent 30  
    fields of view. 
g   Number of nuclei found in syncytia per field of view.  Reported numbers represent 30 fields of view. 
h   Cell-cell fusion as determined by luciferase reporter assay.  Data is normalized to wild-type hPIV3 F.  The reported error indicates 
standard deviations from four triplicate experiments. 
i   Expected phenotype in HRB peptides based on computer modeling by Helori Gaude.  Models created using Swiss Model and 
minimized using the AMBER program. 
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hPIV3 F proteins S477A, I484D, and I484G show surface expression similar to 
expression seen in wt hPIV3 F.  The other 5 mutants (S477K, N478D, N478K, G485A, 
and G485K) show large increases in surface expression ranging from 132% (S477A and 
G485K) to 172% (G485A) of wt surface expression (Fig. 3-2, Table 3-1).  Results 
suggest that mutations are comparable to wt with respect to amount of protein found on 
the cell surface and may even stabilize the F protein in some cases allowing the protein to 
be found in greater quantities on the cell surface.   
 
 
hPIV3 F Proteins Found on the Cell Surface Are Fusion Capable.  Before the 
hPIV3 F protein reaches the cell surface, it is cleaved intracellularly by the protease furin.  
This cleavage is necessary to convert the inactive F0 precursor into a fusion capable 
complex formed by disulfide linked F1 and F2 [19].  To assess efficiency of cleavage of 
the hPIV3 F protein, a radioimmunoprecipitation with a 15 minute 35S pulse and a 120 
minute chase was performed.  Cleavage efficiency was determined as the amount of F1 
divided by total F (F1 + F0) since the F2 subunit was not visible on an SDS-PAGE gel.  
Results show that all mutants are cleaved in similar ratios to F wt.  Despite high surface 
expression of several mutant hPIV3 F proteins, both F wt and mutant F proteins showed 
cleavage efficiencies of only 40% to 55% (Fig. 3-3, Table 3-1).  However, this is most 
likely due to the fact that the samples were whole cell lysates containing both surface and 
intracellular F proteins.  The antibody pulling down both cleaved F1 and F2 surface 
proteins and uncleaved precursor F0 proteins still being processed intracellularly would 
account for the higher presence of F0. 
 
 
 Mutations Have Significant Effects on Cell-Cell Fusion.  To determine the effects of 
the mutations on the fusogenicity of the hPIV3 F protein, Vero cells were transfected 
with both hPIV3 mutant F DNA and hPIV3 HN DNA, fixed, and stained 20 hours later to 
identify cell-cell fusion.  Results from the syncytia assay show that despite similarities in 
expression and intracellular processing, mutations in the HRB region have visible effects 
on cell-cell fusion.  Mutations S477A and N478K have noticeably larger syncytia created 
from the fusion of numerous cells while mutant S477K shows little syncytia formation 
containing fewer fused nuclei (Fig. 3-4).  Since syncytia resulting from the expression of 
mutant F proteins showed differences in number and nuclei per syncytia, counts for both 
were conducted over 30 fields of view to more accurately compare mutation effects.  
Results confirm more syncytia consisting of more nuclei in mutants S477A and N478K 
as well as in the G485 mutants.  As expected, mutants S477K, and I484D showed both 
lower syncytia counts with fewer nuclei (Table 3-1). 
 
To achieve a more quantitative comparison between hPIV3 F mutants, a luciferase 
reporter gene assay was performed.  Vero cells were transfected with a T7 Luciferase 
Control DNA (Promega), pCAGGs C243 hPIV3 F, and pCAGGs C243 HN DNA and 
overlaid with BSR cells constitutively expressing T7 polymerase.  Cell-cell fusion of 
triplicate samples was measured by the amount of luciferase activity detected (Fig. 3-5).  
Results confirm the increase in fusogenicity of mutants S477A, N478K, and G485A and 
a decrease in fusogenicity of mutants S477K and I484D.  Despite minor differences, 
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Figure 3-2.  hPIV3 F Surface Protein as Determined by Surface Biotinylation. (A)  
Vero cells expressing hPIV3 wild-type (wt) or mutant F proteins were labeled with [35S] 
for 15 minutes and chased for 2 hours.  Cells were then biotinylated twice for 15 minutes 
each.  Samples were immunoprecipitated with a polyclonal antibody against the 
cytoplasmic tail of the F protein and incubated with Protein A Sepharose overnight at 
4oC.  Next day, samples were washed and biotinylated hPIV3 F protein was pulled down 
using Streptavidin.  Samples were run on a SDS-PAGE gel under denaturing conditions 
but in the absence of reducing agents.  (B)  Ratios of surface biotinylation as a percentage 
of wt.  Solid line signifies 100% hPIV3 wild-type (wt) biotinylation.   
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Figure 3-3.  Cleavage of Mutant hPIV3 F Proteins.  (A)  Vero cells expressing hPIV3 
F wild-type (wt) or mutant F proteins were labeled with [35S] methionine for 10 minutes 
and chased for 2 hours.  F proteins were immunoprecipitated with a polyclonal antibody 
against the cytoplasmic tail of the F protein and analyzed on a SDS-PAGE gel under 
reducing conditions.  (B)  Ratios of cleaved F proteins. The intensities of the F0 and F1 
bands from A were quantified and the fraction of cleaved F1 was calculated by dividing 
F1 by total F.  F2 protein was not observed in this assay
 18
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Figure 3-4.  Syncytia Assay for Cell-Cell Fusion.  Cell-cell fusion of BHK cells expressing wild-type (wt) or mutant F hPIV3 
protein and hPIV3 HN protein.  20 hours post-transfection were stained with Hema 3 solution (Fischer) according to manufacturer 
instructions.  Representative fields were captured on a Nikon Eclipse TS100 inverted microscope.  Samples transfected with HN only 
or F wt only represent negative controls with no syncytia formation. 
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Figure 3-5.  Luciferase Reporter Gene Assay of Cell-Cell Fusion.  Cell-cell fusion of 
Vero cells transfected with luciferase T7 DNA and expressing wild-type (wt) or mutant F 
hPIV3 protein and hPIV3 HN protein.  16 hours post-transfection Vero cells were 
overlaid with BSR T7/5 cells expressing T7 polymerase for 5 hours at 37ºC.  Reported 
luciferase activity was normalized to wt.  Asterisks indicate a significant difference from 
wild-type as determined by the Student’s t-test (P≤0.05).  Luciferase data represents four 
sets of triplicate experiments.  Solid line signifies 100% hPIV3 wild-type cell-cell fusion. 
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results from the luciferase reported gene assay generally confirm observations made in 
the syncytia fusion assay.   
 
 
Discussion 
 
 Studies investigating the effects of mutations in the HRB region of the hPIV3 F 
protein have proved to be relatively consistent with results obtained through computer 
modeling.  In mutations such as S477A, N478D, N478K, and G485A expected to 
destabilize the HRB region of the F protein, total expression and cleavage are seen at  
levels similar to wt but there is an increase in fusogenicity.  An increase in fusogenicity is 
expected from destabilizing mutations because by making interactions in the HRB region 
weaker, the protein would have a greater tendency to move into its lower energy, final 
fusogenic form and increase the amount of cell-cell fusion seen in both syncytia and 
luciferase reporter gene assays.  However, with the exception of S477K, all the observed 
destabilizing mutants show an increase in cell surface expression of the F protein which 
may account for increased cell-cell fusion.  To further investigate these mutants and 
determine the effect of a higher surface expression, a DNA titration assay could be 
performed to compare levels of transfected DNA to cell-cell fusion as determined by the 
luciferase reported gene assay.  Transfection of differing amounts of DNA will determine 
if the increase in fusion is due to a destabilization of the pre-fusion F protein structure or 
simply due to an increase in the number of fusion proteins found on the cell surface. 
  
Similarly, the mutation I484D, which lies on the interior of the triple stranded coiled 
coil at position ‘d’ (Fig. 3-6), was expected to stabilize the F protein and was 
characterized by similar expression, cell surface expression, and cleavage as well as a 
decrease in cell-cell fusion in both syncytia and luciferase assays.  The mutation of a 
nonpolar isoleucine residue to an acidic aspartic acid residue may stabilize the F protein 
in its native structure by creating strong interactions with basic residue K480 on an 
adjacent coil.  Interactions between these two residues would create strong enough 
interactions to promote the pre-fusion conformation of the F protein, causing a decrease 
in the formation of the final fusogenic form of the protein and therefore a decrease in the 
amount of cell-cell fusion observed.  However, the second mutant expected to stabilize 
the HRB triple stranded coiled coil structure showed very little difference from the wt F 
protein.  The mutation G485K was expected to stabilize the pre-fusion F structure 
according to the thermodynamic potentials obtained through computer modeling but 
instead showed expression, cleavage, and cell-cell fusion levels similar to wt.  Despite 
reported increase in the number of syncytia per field and the number of syncytial nuclei 
per field, the luciferase assay reports cell-cell fusion levels similar to those reported in wt.  
This discrepancy can be explained by taking into consideration the position of residue 
485.  Due to residue 485 being located at an ‘e’ position, the side chains of the residue 
would be interacting primarily with solvent molecules as opposed to adjoining amino 
acid side chains and therefore would play little or no part in the stability of the F protein 
as a whole. 
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Figure 3-6.  Schematic of the Three Helix Bundle.  To visualize the placement of 
residues within the three-helix bundle the above model was created.  Residues ‘a’ and ‘d’ 
are found on the interior hydrophobic surface of the triple stranded coiled coil 
conformation, while residues ‘b’, ‘c’, ‘e’, ‘f’, and ‘g’ show less side chain interactions 
and have a lesser effect on bundle stability. 
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Finally, two mutations were chosen as having little or no effect on the stability of the F 
protein as determined by modeling and derived thermodynamic potentials.  However, 
both mutations I484G and S477K showed increased stabilization as determined by cell-
cell fusion assays.  The first mutation, I484G, is located at a ‘d’ position and therefore 
directly influences the packing of the amino acid side chains within the triple stranded 
coiled coil.  By removing isoleucine and replacing it with a glycine, which has a 
significantly smaller side chain, internal residues may be able to pack tighter and 
therefore increase the energy needed to separate the three helix bundle at the initiation of 
fusion.  Alternatively, mutation S477K, also located at a ‘d’ position, replaces an interior 
serine with the much larger side chain of lysine.  According to the computer models 
generated by Helori, there are very few differences in the number of possible 
Vanderwaals interactions between the original serine at position 477 and the lysine 
mutation.  However, the length and flexibility of the lysine side chain create a hydrogen 
bond with asparagine 478 which would contribute to the stability of the pre-fusion 
conformation of the F protein and result in decreased cell-cell fusion (Fig. 3-7).  In 
addition, the models show the insertion of one lysine side chain straight into the middle 
of the three helix bundle.  There is a possibility that this residue is able to fill the interior 
cavity of the three helix bundle and therefore exclude solvent molecules, also resulting in 
an increase in stability of the pre-fusion F protein conformation.  Due to the flexible 
nature of the lysine residue, further modeling may contribute to our understanding of this 
mutant.  Since the created models only show one possible position of the lysine residues, 
alternate models could be helpful in further determining additional interactions 
contributing to the stabilization of the pre-fusion F protein. 
 
Based on the information obtained in our studies, we believe the HRB region of the 
hPIV3 F protein is found in a triple stranded coiled coil conformation in the pre-fusion 
structure.  My analyses of the interactions responsible for changes in F protein stability 
are based on models representing only the HRB region, with the assumption that these 
models represent the HRB region in the full length F protein as well.  The creation of 
full-length F protein models would be another useful tool in verifying the side chain 
interactions observed in the HRB models.  Although there are some differences between 
estimated thermodynamic potentials and actual stabilities observed in F protein mutants, 
further analysis of amino acid side chain interactions in computer models can account for 
observed differences.  The creation of more complex computer models which take into 
consideration differences in side chain positioning can be further investigated to further 
understand experimental results.   
  
 
  
 
 
 
 
 
 
 
 
 
Figure 3-7.  Side Chain Interactions in Mutant S477K.  Using previously generated 
models, possible Vanderwaals interactions and hydrogen bonding was assessed.  Lysine’s 
flexibility allows at least 2 Vanderwaals interactions per residue and allows for a 
hydrogen bond between the lysine at position 477 and adjacent asparagine 478.  Mutated 
residues S477K are represented in red.   
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Chapter 4.  Construction and Solubilization of hPIV3 Peptides 
 
 
Introduction 
 
Biochemical and structural studies have shown that the fusion (F) protein undergoes a 
series of conformational changes.  Two distinct structures have been solved for the F 
protein by Yin et. al.  The structure of the human parainfluenza virus 3 (hPIV3) F protein 
shows both the heptad repeat A (HRA) and the heptad repeat B (HRB) in a hairpin 
conformation, a hallmark of the post-fusion conformation [11]. On the other hand, the 
recently solved structure of the parainfluenza virus 5 (PIV5) F protein is believed to 
represent the native conformation of the F protein [3]. 
 
Studies have confirmed the dramatic conformational changes in the heptad repeat A 
(HRA) and heptad repeat B (HRB) regions of the paramyxovirus F protein [2, 3, 4, 15].  
However, several biochemical observations need to be reconciled with the structural data.  
For example, in previous studies HRA peptides have been found to spontaneously fold 
into a triple stranded coiled coil conformation [20] while peptides derived from the HRB 
region have been found primarily a random coil conformation [20, 21].  However, when 
HRB is placed in a solution with HRA the two peptides bind in an antiparallel manner to 
form a six helix bundle which drives the fusion of the viral and cell membranes [20, 22].  
These observations suggest that the HRB region is unstable and requires the assistance of 
other domains to remain structured. In the pre-fusion PIV5 F structure the HRB region is 
found in a triple stranded coiled coil conformation [6].  Due to the tendency of the F 
protein to refold into its final fusogenic form when the transmembrane domain directly 
adjacent to the HRB region is deleted [11], some structural studies have proceeded by 
attaching a trimerization domain to the c-terminus of the HRB region in an effort to 
stabilize the pre-fusion conformation [11, 23, 24].  Despite suggestions that the 
trimerization domain has little or no effect on the formation of the HRB secondary 
structure [6] question still arise regarding the conformation of the HRB region.  Is the 
HRB region actually found in a triple stranded coiled coil structure? Is the secondary 
structure of the HRB a result of the attached trimerization domain?   
 
To determine the effect of a trimerization domain on HRB conformation a series of 
peptides assays were suggested.  Computer modeling by a previous student, Helori 
Gaude, allowed a number of mutations to be chosen based on their ability to disrupt or 
stabilize the three helix bundle of the HRB region as determined by an estimated 
thermodynamic potential (Fig. 4-1) from modeling programs Swiss-Model and AMBER. 
The creation of an HRB peptide attached to a trimerization domain, and carrying various 
mutations will allow us to assess the effect of the trimerization domain on secondary 
structure.  Mutations meant to disturb the formation of a three helix bundle and resulting 
in expected stabilization or destabilization of the three helix bundle will confirm the 
nature of the HRB region.  We propose that the addition of a trimerization domain does 
not alter HRB conformation and that the HRB region is indeed found in a triple stranded 
coiled coil conformation.
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Figure 4-1.  Thermodynamic Potential of Mutations in the HRB Region of hPIV3.  Thermodynamic calculations for mutations in 
the HRB region were completed by Helori Gaude using the Swiss-Model program and were minimized using the AMBER program.  
Mutations were chosen based on the ability to either destabilize or stabilize a three helix bundle of the HRB peptide.  Control 
mutations S477K and I484G were expected to cause little or no change in HRB stability. LAH 
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Materials and Methods 
 
 
Creation of Plasmids Containing the HRA and HRB Peptides.  Residues 136 to 191 
from the hPIV3 F protein were initially subcloned from the pGEX4TI hPIV3 N56 
plasmid (provided by the Lamb lab) into a pET15b background by Helori Gaude using 
BamHI and SalI restriction sites.  Point mutations were generated by Helori Gaude using 
the QuickChange site-directed mutagenesis kit (Stratagene) (data not shown).  The hPIV3 
F HRBGC pET15b plasmid was subcloned by John Mason from a puc vector synthesized 
by Blue Heron Biotechnology, Inc. into a pET15b background using BamHI and SalI 
restriction sites to create the HRB peptide. This construct contains residues 454 to 486 
from the hPIV3 F protein and a GCN4 domain.  Both constructs contain an N terminal 
His tag, thrombin cleavage site, and Factor Xa (FXa) cleavage site (Fig. 4-2).  Finally, 
residues 454 to 486 from the hPIV3 F protein were subcloned into pMAL – c2E (New 
England Biolabs, N8066S) using BamHI and SalI restriction sites.  Sequences of plasmid 
constructs were confirmed by the Hartwell Center of St. Jude Children’s Research 
Hospital. 
 
 
Solubilization of Peptides Using Decreasing Urea Concentrations.  Insoluble 
peptides were those found in the pellet as opposed to the supernatant after induction and 
lysis.  The pellet containing the insoluble peptide was resuspended in 7 M urea.  Urea 
was added in volume twice the weight of the pellet and 5 mM β-mercaptoethanol (βME) 
was added.  The solution was vortexed until completely resuspended and then loaded into 
a 3,500 MWCO Slide-A-Lyzer Casette (Pierce) for dialysis.  Every 16 – 18 hr the casette 
was changed over into solution containing less urea.  Solutions for dialysis included 150 
mM NaCl, 5 mM βME, and either 7 M, 3 M, 1 M, or 0 M urea.  Dialysis occurred at 4°C. 
 
 
Solubilization of Peptides Using a Decrease in pH.  Limited success with previous 
solubilization methods led to an alternate approach based on recommendations from the 
QIAexpressionist handbook (Qiagen).  Pellets were resuspended in lysis buffer and then 
spun down for 30 min at 27,000 x g at 4°C in an Optima L-90K ultracentrifuge 
(Beckman).  The supernatant was removed and the pellet was resuspended in a non-ionic 
detergent buffer containing 20 mM Tris, 200 mM KCl, and 0.5% Triton-X100 and spun 
down.  The supernatant was removed and the pellet was resuspended a third time in a 
solution containing 10 mM Tris, 100 mM NaH2PO4, and 7 M urea at an initial pH of 8.0 
and spun down.  The supernatant was loaded into a Ni column and washed with once (3 
bed volumes) with solutions containing 10 mM Tris, 100 mM NaH2PO4, and 7 M urea 
with each subsequent solution dropping in pH (pH 8.0, 6.3, 5.9, and 4.5).  Flow through 
was collected from all washes in 1 ml fractions.  Fractions containing peptide of interest 
were then dialyzed from 7 M urea to 0 M urea using a 5 mM KCl solution including 5 
mM βME. 
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Spacer Fxa 
 
 
 
Figure 4-2.  Peptide Constructs.  hPIV3 F HRB and HRA sequences subcloned initially 
into pET15b vectors.  Constructs contain a six amino acid histidine tag (His), a thrombin 
cleavage site (Thrombin), and a FXa cleavage site (FXa) attached to the n-terminal end of 
the heptad repeat region.  The HRB peptide also contains a 23 amino acid trimerization 
domain attached to its C-terminus.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HRB (C33) Trimerization domain  
Hi
Thrombin 
HRA (N56) His 
5’ 3’ 
5’ 3’ 
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Solubilization of Peptides in a Low Salt and Low pH Solution.  The third method of 
solubilization included a decrease in urea concentration accompanied by a low salt 
concentration and acetate to lower the pH of the solution.  Fractions obtained by washes 
with low pH solutions through the Ni column underwent dialysis in 20 mM acetate 
(Sigma) solutions (pH 5.0) including 5 mM KCl, 5 mM βME, and decreasing 
concentrations of urea (7 M, 3 M, 1 M, and 0 M).  Solubilization of peptides was 
confirmed by ultracentrifugation for 1 hr at 100,000 x g and 4°C in an Optima L-90K 
ultracentrifuge (Beckman).   
 
 
Results  
 
 
HRA Purification.  Since the HRA region of hPIV3 has been shown to be a promoter 
of HRB secondary structure when incubated together [20, 22] we wanted to create and 
purify a HRA peptide to examine the effects of mutations in the hPIV3 F HRB region on 
formation of the six helix bundle.  The HRA peptide was created by the Protein 
Production Facility of St. Jude Children’s Hospital where it was purified through a nickel 
column and cleaved with thrombin.  In order to remove the thrombin and prevent peptide 
degradation, samples were run though a Benzamidine Sepharose 6B (GE Healthcare) 
column which contains p-aminobenzamidine, a synthetic inhibitor of serine proteases 
such as thrombin.  Samples were collected and visualized on a 16% Tricine gel 
(Invitrogen).  Resulting gels show a peptide band running at the expected 8.8 kDa  
(Fig. 4-3) although the presence of additional bands suggest further purification will be 
needed to determine the effect of mutations in HRB and their ability to interact with HRA 
to form a six helix bundle.            
 
 
Solubility of HRBGC Peptides.  To assess the secondary structure of the hPIV3 HRB 
region initial experiments were carried out only on the hPIV3 F wt peptide until a 
successful protocol could be established.  BL-21 CodonPlus (DE3)-RIPL cells were 
transformed by heat-pulse with a plasmid containing the HRB sequence and a 
trimerization domain (HRBGC) and induced with IPTG (Fig. 4-4A).  Despite the 
appearance of small amounts of HRBGC peptide after purification through a Ni column, 
the majority of the peptide was found to be in pellet samples suggesting that the peptide 
remained within the BL-21 CodonPlus (DE3)-RIPL cell membrane and is therefore 
insoluble (Fig. 4-4C).   
  
Previous studies on the ability of urea to reversibly denature and solubilize peptides 
[25, 26] prompted the use of decreasing urea concentrations to solubilize the peptide and 
then allow refolding without aggregation.  After induction and lysis, the remaining pellet 
containing the insoluble peptide was resuspended in a 7 M urea solution under reducing 
conditions.  Peptides in 7 M urea and 150 mM NaCl underwent dialysis into solutions 
containing lower urea concentrations.  Precipitate was seen when the peptide solution 
was put into a 1 M urea dialysis solution.  Despite the lower urea concentration, 
subsequent assays needed to determine HRB secondary structure would require a  
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Figure 4-3.  Benzamidine Sepharose Column Purification of HRA.  Thrombin 
cleaved HRA peptides were run through a Benzamidine Sepharose 6B (GE Healthcare) 
column to remove excess thrombin.  Visualization on a 16% Tricine gel (Invitrogen) 
shows purity of HRA after column purification.  Each column represents a 1 ml fraction. 
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Figure 4-4.  Solubilization of the HRBGC Peptide.  (A)  pET15b plasmids containing 
the hPIV3 F HRB sequence with an attached trimerization domain were transformed into 
BL-21 CodonPlus(DE3)-RIPL cells and induced with 100 μM IPTG.  Cells showed an 
increase in peptide production (lane 2) as opposed to an un-induced control (lane 1).  (B)  
HRBGC peptides solubilized under low pH and low salt conditions were analyzed before 
(lane 1) and after ultracentrifugation (lane 2) to verify solubility.  (C)  Visualization of 
the HRBGC peptide after induction. Lanes 1 and 2 represent samples taken before cell 
lysis.  Lanes 3 and 4 represent the supernatant and pellet samples after cell lysis.  Lanes 
5-9 represent flow through samples after Ni purification. (D)  Fractions of HRBGC 
peptide after dialysis into a low pH (5.0) and low salt (5 mM KCl) solution and 
purification through a Ni column.  Lanes represent soluble HRBGC fractions after 
passage through the column and collection in 1 ml samples. 
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complete absence of urea and therefore further exploration into methods for peptide 
solubilization were necessary.  
 
Based on evidence that protonation of charged residues (H, R, K, D, and E) increases 
solubility of aggregate peptides [27] dialysis of aggregate HRBGC peptides in low pH 
solutions was considered.  The HRBGC peptide has 33% charged residues and therefore 
may be good candidate for solubilization via protonation.  Methods of solubilization and 
purification via changes in pH were per instructions in the QIAexpressionist handbook 
(Qiagen).  Insoluble peptides were resuspended in a 7 M urea solution at pH 8.0 and then 
loaded into a Ni column.  The column was washed with buffers containing 7 M urea and 
decreasing pH values.  The fractions containing the majority of peptide appeared as 
expected at pH 4.5 and included noticeably less non-specific peptides as well as being 
aggregate free (Fig. 4-4D).  However, many of the subsequent assays would require the 
peptides to be solubilized in a urea free solution.  Attempts to bring the peptides back to 
urea free conditions via dialysis in a low pH buffer were unsuccessful. 
  
In a third attempt to find correct solubilization conditions acetate was used to maintain 
a low pH and the salt concentration was reduced from 150 mM to 5 mM.  Dialysis was 
used to move the peptides from a solution containing 7 M urea to one containing no urea 
at pH 5.0.  Peptides remained soluble throughout dialysis and solubility was confirmed 
with ultracentrifugation (Fig. 4-4B).  In a low salt and low pH solution peptides remained 
soluble as demonstrated by the absence of precipitate seen in the samples.     
 
 
Cleavage by Factor Xa.  In order to prevent inhibition of peptide secondary structure, 
the additional His tag and thrombin cleavage site were removed by proteolytic cleavage 
by FXa.  Despite confirmation of the proper FXa cleavage site by sequence analysis, 
visualization of cleavage of the HRA peptide was minimum (Fig. 4-5A) although a gel 
shift could be seen suggesting cleavage had occurred.   
 
An additional 250 µl of FXa was added to the HRBGC peptide sample based on the 
appearance of a precipitate assumed to be the FXa.  The appearance of precipitate can be 
explained by the 4.9 to 5.2 isolelectric point (pI) of FXa which suggests that FXa has less 
solubility in the range of pH 4.9 to 5.2.  The precipitate was confirmed to be FXa as 
opposed to the HRBGC peptide by visualization on an SDS-PAGE gel (Fig. 4-5B).  
Despite the increase in precipitate seen after the addition of FXa there was no decrease in 
the amount of peptide seen on the gel.  These results confirm that the precipitate was the 
consequence of the FXa being in a low pH solution and not aggregation of the HRBGC 
peptide. 
 
 
Concentration of Peptides.  Samples of HRBGC peptide resulting from column 
purification had lower concentrations of peptide per fraction and therefore would need to 
be concentrated in order to effectively use them for subsequent purification assays such 
as high-performance liquid chromatography (HPLC) where they would be further diluted.   
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Figure 4-5.  Cleavage of Peptides by Factor Xa.  (A)  Visualization of the efficiency of 
FXa cleavage on the HRA peptide (lane 2) in comparison to an uncleaved control  
(lane 1).  (B)  The efficiency of FXa cleavage on the HRBGC peptide (lane 2). Lane 3 
represents HRBGC cleavage after the addition of extra FXa and a longer incubation 
period. Both cleaved samples are compared to an uncleaved HRBGC control (lane 1). 
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Samples were loaded into a Centrifugal Filter Device (Millipore) and concentrated on an 
Eppendorf microcentrifuge.  Resulting solutions showed large amounts of precipitate 
after centrifugation.  Despite the success in solubilizing the HRBGC in low pH and low 
salt solutions, the inability to concentrate it proved to be problematic and therefore 
necessitated alternate methods of acquiring soluble HRBGC. 
 
 
MBP Construct.  Based on several studies indicating maltose binding protein (MBP) 
as an effective promoter of solubility [28-30] the hPIV3 F wt HRBGC peptide was 
subcloned into a MBP background.  Sequences of the resulting plasmid were confirmed 
by the Hartwell Center of St. Jude Children’s Research Hospital.  The ease and success of 
subcloning the insoluble HRBGC peptide into MPB, a vector suggested as an effective 
chaperone for protein folding [29], holds promise as a method for quick and relatively 
inexpensive production of mutant hPIV3 F HRB peptides which then can be used in 
subsequent assays to determine HRB secondary structure. 
 
 
Discussion 
 
The ease of purification and cleavage of the HRA peptide in contrast to the difficulties 
encountered with the solubilization of the HRBGC peptide may be explained by a couple 
key differences between the peptides.  As reported earlier, the HRA peptide alone easily 
folds into a triple stranded coiled coil conformation whereas the HRB peptide is found in 
an unstructured random coil conformation [20, 21].   This suggests the unstable and 
entropic nature of the HRB peptide and the necessity of the addition of additional 
components to ensure proper folding and prevent aggregation.  
 
There are a series of possible explanations for the presence of precipitate in HRB 
samples including the possibility that the peptide does not readily fold into its native 
structure, associates with other peptide molecules, and forms insoluble aggregates [29] 
although further structural analysis would be necessary to confirm any hypotheses 
regarding HRB aggregation.  Attempts to coax the peptide into proper folding through 
protonation by suspension in a solution with a low pH [27] were minimally successful.  
HRBGC peptides were able to be solubilized but only under low salt, low pH conditions, 
and only at low peptide concentrations which limits the peptides usefulness in 
downstream applications.  Additional attempts to use urea as a solubilizing agent [25, 26] 
were also unsuccessful in providing a useful, soluble peptide.  The failure of urea to 
promote proper folding of the peptide and therefore prevent aggregation may be due to 
the way urea interacts with both the peptide and the water molecules.  Studies suggest 
that urea actually decreases the mobility of the water molecules around the peptide by 
trapping them between the peptide and the urea molecules and therefore allows for 
increased hydrogen bonding to the peptide and higher solubility [26, 31].  Despite this 
encouraging information there is no evidence that a decrease in urea concentration will 
promote proper refolding. In fact since the urea does not seem to be directly contacting 
the peptide the inability to dissolve the HRBGC peptide may suggest that the removal of 
urea in solution would simply increase the mobility of the water molecules surrounding 
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the peptide, the breaking of hydrogen bonds, and increase the tendency of the 
hydrophobic residues to form insoluble aggregates. 
 
 The association of the HRBGC peptide with MBP, initially used as a method of 
protein purification [33], has become increasingly more popular as a method of peptide 
solubilization and holds promise for the solubilization of the HRBGC peptide.  Among 
the many substrate-binding proteins that have been previously studied, MBP stands out as 
an effective solubilizing agent able to sterically hinder aggregation [28] and also assist 
folding in a similar manner as a protein chaperone [28-30, 33].  Since the HRBGC 
appears to incorrectly fold in the presence of chemical agents, association with MBP 
made lead to a successful solubilization of the peptide in conditions suitable for 
downstream applications. Further investigation is needed in order to determine the 
attachment of MBP as a potential solution for peptide solubility.  FXa cleavage will also 
be an important determinate in whether the peptide can be cleaved from MBP and still 
remain soluble.  Cleavage and resulting soluble peptides will confirm the ability of MBP 
to act as chaperone and promote proper folding of the HRBGC peptide.  
 
 The work surrounding both the HRA and HRBGC peptides is still underway and will 
require the more efficient purification of both peptides by HPLC as well as confirmation 
by mass spectroscopy.  The effective solubilization and purification of heptad repeat 
regions of the hPIV3 will allow the assessment of peptide structure and stability via a 
variety of analyses.  First, the creation of mutations in the HRB region will provide useful 
information about the ability of the mutant HRB peptide to form a six helix bundle when 
incubated with HRA and visualizes on an SDS-PAGE gel.  Circular dichroism (CD) can 
be used to analyze both peptide secondary structure as well as peptide stability through 
thermal melts.  Additional studies could also include analytical ultracentrifugation which 
would determine composition of peptide structure by identifying expected trimeric 
complexes. 
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Chapter 5. Discussion 
 
 
The dramatic conformational changes that occur in the heptad repeat B (HRB) region 
of the paramyxovirus F protein models [5, 10] and the current representative models [6, 
11] raise a variety of questions about the secondary structure of the paramyxovirus F 
protein.  Studies focusing on the HRB region will lead to a greater understanding of how 
the process of fusion between viral and cell membranes is initiated [10] as well as 
defining the role of the HRB region in F protein conformational changes and the 
formation of the final fusogenic hairpin structure.  To date, the study of the 
paramyxovirus F protein has been largely based on the original crystal structure of the 
uncleaved, pre-fusion PIV5 F protein obtained by Yin et. al. in 2006 [6].  Assumptions 
that the HRB region is found in a triple stranded coiled coil conformation has shaped our 
understanding of the F protein and has the potential to influence the way drug 
therapeutics and vaccines against paramyxoviruses are designed.  The research conducted 
in our lab on the effect of mutations in the pre-fusion F protein of hPIV3 shows potential 
in verifying the triple stranded coiled coil nature of the HRB region.  Although still 
underway, assays conducted in both the pre-fusion F protein as well in peptides 
representing the HRB region will be able to verify the structure of this region. 
 
When considering the role of the HRB region in viral and cell membrane fusion, the 
current model raises questions regarding the interaction of the HRB region with the HN 
protein in the initiation of fusion as well as the initiation of viral fusion beginning at the 
breaking apart of the three helix bundle.  The HRB region of the paramyxovirus F protein 
is a region of considerable importance since it has the effect to further explain how the F 
protein surpasses the energy barrier necessary for the breaking of a triple stranded coiled 
coil conformation.   
 
In discussing the importance of understanding the HRB region, the results obtained 
from the pre-fusion conformation of the hPIV3 F protein will be greatly enhanced by 
further study of peptides created from the sequence of this region.  Results from the 
solubilization and purification of both the HRA and HRBGC peptides highlight the 
unique issues surrounding peptide-based experimentation as well as the success rate for 
peptide-based candidates for drug therapy [34].  There is reason to assume that the pre-
fusion F protein will be used as a drug target by labs designing peptides to bind to pre-
fusion intermediates and therefore prevent fusion and viral replication [35, 36].  Several 
labs are already in the process of creating effective drug therapies based on the concept of 
peptide inhibition of fusion intermediates.  These include experiments designed to test the 
potency of peptides derived from differing paramyxoviruses [37] as well as the 
effectiveness of peptides varying in length [38].  To date, it appears that the peptides, 
especially the HRB derived peptides, are the most effective inhibitors of viral fusion [37, 
38] and therefore warrant further investigation as effective inhibitors of viral replication. 
 
In closing, future work based in the area of the HRB region of the paramyxovirus F 
protein holds potential in developing our understanding of viral fusion and in the 
development of effective therapeutics aimed at decreasing viral spread.  With the success 
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of the hPIV3 HRB derived peptides as potent inhibitors of the final fusogenic form of the 
F protein, knowledge of this region will increase understanding of how to create more 
effective peptide inhibitors that can be carried into clinical trial in the near future. 
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